SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ 2005 Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 14: 590595.
  • 2
    Feldman D, Malloy PJ, Krishnan AV, Balint E 2007 Vitamin D: Biology, action and clinical implications. MarcusR, FeldmanD, NelsonDA, RosenCJ (eds.) Osteoporosis, vol 1. Academic Press, San Diego, CA, USA, 317382.
  • 3
    Chen TC, Holick MF 2003 Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 14: 423430.
  • 4
    Deeb KK, Trump DL, Johnson CS 2007 Vitamin D signaling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer 70: 684700.
  • 5
    Krishnan AV, Peehl DM, Feldman D 2003 Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 88: 363371.
  • 6
    Krishnan AV, Peehl DM, Feldman D 2005 Vitamin D and prostate cancer. FeldmanD, PikeJW, GlorieuxFH (eds.) Vitamin D, vol 2. Elsevier Academic Press, San Diego, CA, USA, 16791707.
  • 7
    Peehl DM, Krishnan AV, Feldman D 2003 Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 133: 2461S2469S.
  • 8
    Stewart LV, Weigel NL 2004 Vitamin D and prostate cancer. Exp Biol Med (Maywood) 229: 277284.
  • 9
    Nelson WG, De Marzo AM, Isaacs WB 2003 Prostate cancer. N Engl J Med 349: 366381.
  • 10
    Hanchette CL, Schwartz GG 1992 Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70: 28612869.
  • 11
    Schwartz GG, Hulka BS 1990 Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10: 13071311.
  • 12
    Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary J 1985 Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 76: 470473.
  • 13
    Giovannucci E 2005 The epidemiology of vitamin D and cancer incidence and mortality: A review (United States). Cancer Causes Control 16: 8395.
  • 14
    Corder EH, Friedman GD, Vogelman JH, Orentreich N 1995 Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: Risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 4: 655659.
  • 15
    Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N 1993 Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2: 467472.
  • 16
    Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA 1996 Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 56: 41084110.
  • 17
    Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM 2003 Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev 12: 2327.
  • 18
    Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF 2003 Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem 88: 315322.
  • 19
    Hsu JY, Feldman D, McNeal JE, Peehl DM 2001 Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 61: 28522856.
  • 20
    Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF 1998 Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 7: 391395.
  • 21
    Gross C, Stamey T, Hancock S, Feldman D 1998 Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159: 20352039.
  • 22
    Bouillon R, Okamura WH, Norman AW 1995 Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16: 200257.
  • 23
    Ma Y, Khalifa B, Yee YK, Lu J, Memezawa A, Savkur RS, Yamamoto Y, Chintalacharuvu SR, Yamaoka K, Stayrook KR, Bramlett KS, Zeng QQ, Chandrasekhar S, Yu XP, Linebarger JH, Iturria SJ, Burris TP, Kato S, Chin WW, Nagpal S 2006 Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest.
  • 24
    Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P 1998 Model systems of prostate cancer: Uses and limitations. Cancer Metastasis Rev 17: 361371.
  • 25
    Blutt SE, Allegretto EA, Pike JW, Weigel NL 1997 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138: 14911497.
  • 26
    Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP 1997 Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19: 1527.
  • 27
    Yang ES, Burnstein KL 2003 Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 278: 4686246868.
  • 28
    Blutt SE, McDonnell TJ, Polek TC, Weigel NL 2000 Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141: 1017.
  • 29
    Boyle BJ, Zhao XY, Cohen P, Feldman D 2001 Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165: 13191324.
  • 30
    Peng L, Malloy PJ, Feldman D 2004 Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 18: 11091119.
  • 31
    Stewart LV, Weigel NL 2005 Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate 64: 919.
  • 32
    Johnson CS, Hershberger PA, Trump DL 2002 Vitamin D-related therapies in prostate cancer. Cancer Metastasis Rev 21: 147158.
  • 33
    Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D 2004 Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 59: 243251.
  • 34
    Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD, Feldman D 2004 Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 92: 131141.
  • 35
    Nonn L, Peng L, Feldman D, Peehl DM 2006 Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: Implications for prostate cancer prevention by vitamin D. Cancer Res 66: 45164524.
  • 36
    Badawi AF 2000 The role of prostaglandin synthesis in prostate cancer. BJU Int 85: 451462.
  • 37
    Hussain T, Gupta S, Mukhtar H 2003 Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191: 125135.
  • 38
    Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D 2005 Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 65: 79177925.
  • 39
    Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H 2000 Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42: 7378.
  • 40
    Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada S 2000 Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89: 589596.
  • 41
    Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM, Garzotto M 2005 Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem Biophys Res Commun 332: 800807.
  • 42
    Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB 2001 Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 61: 86178623.
  • 43
    Rubio J, Ramos D, Lopez-Guerrero JA, Iborra I, Collado A, Solsona E, Almenar S, Llombart-Bosch A 2005 Immunohistochemical expression of Ki-67 antigen, Cox-2 and Bax/Bcl-2 in prostate cancer: Prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 31: 31.
  • 44
    Cohen BL, Gomez P, Omori Y, Duncan RC, Civantos F, Soloway MS, Lokeshwar VB, Lokeshwar BL 2006 Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 119: 10821087.
  • 45
    De Marzo AM, Nakai Y, Nelson WG 2007 Inflammation, atrophy and prostate carcinogenesis. Urol Oncol 25: 398400.
  • 46
    Wang W, Bergh A, Damber JE 2005 Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11: 32503256.
  • 47
    Chen Y, Hughes-Fulford M 2000 Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br J Cancer 82: 20002006.
  • 48
    Narayanan BA, Narayanan NK, Davis L, Nargi D 2006 RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: Modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther 5: 11171125.
  • 49
    Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K, Markowitz SD 2004 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 101: 1746817473.
  • 50
    Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD 2006 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 103: 1209812102.
  • 51
    Topol EJ 2004 Failing the public health—rofecoxib, Merck, and the FDA. N Engl J Med 351: 17071709.
  • 52
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ 2000 Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 15201528.
  • 53
    Beer TM, Lemmon D, Lowe BA, Henner WD 2003 High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97: 12171224.
  • 54
    Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG 2003 Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 22: 43144332.
  • 55
    Culig Z, Steiner H, Bartsch G, Hobisch A 2005 Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95: 497505.
  • 56
    Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS 1999 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 59: 26442649.
  • 57
    Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL 2001 Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel- induced apoptosis. Clin Cancer Res 7: 10431051.
  • 58
    Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS 2006 Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 106: 21362142.
  • 59
    Beer TM, Ryan CW, Venner PM, Pertrylak DP, Chatta GS, Ruether D, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner D, Arroyo A, Clow FW 2007 A double-blinded randomized study of DN-101 high-dose calcitriol plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT Investigators. J Clin Oncol 25: 669674.
  • 60
    De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Issacs WB, Nelson WG 2007 Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256264.
  • 61
    Lucia MS, Torkko KC 2004 Inflammation as a target for prostate cancer chemoprevention: Pathological and laboratory rationale. J Urol 171: S30S34.
  • 62
    Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J 1998 Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br J Urol 81: 730734.
  • 63
    Nelson JE, Harris RE 2000 Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): Results of a case-control study. Oncol Rep 7: 169170.
  • 64
    De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG 2004 Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 91: 459477.
  • 65
    Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, Mukhtar H 2004 Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64: 33343343.
  • 66
    Alagbala A, Moser MT, Johnson CS, Trump DL, Posner GH, Foster BA, 2005 Prevention of prostate cancer progression with vitamin D compounds in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Fourth annual AACR International Conference on Frontiers in Cancer Prevention Research, Baltimore, MD, USA, October 30 to November 2, 2005.
  • 67
    Alagbala AA, Moser MT, Johnson CS, Trump DL, Posner GH, Foster BA, 2006 1a, 25-dihydroxyvitamin D3 and its analog (QW-1624F2-2) prevent prostate cancer progression. 13th Workshop on Vitamin D, Victoria, British Columbia, Canada, April 8–12, 2006.
  • 68
    Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, DiPaola RS, Abate-Shen C 2006 Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res 12: 58955901.
  • 69
    Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta G, Ruether JD, Henner WD, Chi KN, Cruickshank S, Investigators A 2005 Interim Results From ASCENT: A Double-Blinded Randomized Study of DN-101 (High-Dose Calcitriol) Plus Docetaxal vs. Placebo Plus Docetaxal in Androgen-Independent Prostate Cancer (AIPC). American Society of Clinical Oncology, Orlando, FL, USA.
  • 70
    Trump D, Lau YK 2003 Chemotherapy of prostate cancer: Present and future. Curr Urol Rep 4: 229232.
  • 71
    Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta G, Dean Ruether J, Chi KN, Curd JG, DeLoughery TG 2006 High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol 135: 392394.
  • 72
    Koyama T, Shibakura M, Ohsawa M, Kamiyama R, Hirosawa S 1998 Anticoagulant effects of 1alpha,25-dihydroxyvitamin D3 on human myelogenous leukemia cells and monocytes. Blood 92: 160167.
  • 73
    Aihara K, Azuma H, Akaike M, Ikeda Y, Yamashita M, Sudo T, Hayashi H, Yamada Y, Endoh F, Fujimura M, Yoshida T, Yamaguchi H, Hashizume S, Kato M, Yoshimura K, Yamamoto Y, Kato S, Matsumoto T 2004 Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 279: 3579835802.